RS-102221 is a drug developed by Hoffmann–La Roche, which was one of the first compounds discovered that acts as a potent and selective antagonist at the serotonin 5-HT2C receptor, with around 100x selectivity over the closely related 5-HT2A and 5-HT2B receptors. It has anxiolytic effects in animal studies, increases the effectiveness of SSRI antidepressants, and shows a complex interaction with cocaine, increasing some effects but decreasing others, reflecting a role for the 5-HT2C receptor in regulation of the dopamine signalling system in the brain.
Property | Value |
---|---|
dbo:abstract |
|
dbo:casNumber |
|
dbo:chEMBL |
|
dbo:pubchem |
|
dbo:thumbnail | |
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink |
|
dbp:c |
|
dbp:casNumber |
|
dbp:chembl |
|
dbp:chemspiderid |
|
dbp:f |
|
dbp:h |
|
dbp:iupacName |
|
dbp:iupharLigand |
|
dbp:n |
|
dbp:o |
|
dbp:pubchem |
|
dbp:s |
|
dbp:smiles |
|
dbp:stdinchi |
|
dbp:stdinchikey |
|
dbp:synonyms |
|
dbp:verifiedfields |
|
dbp:verifiedrevid |
|
dbp:width |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
gold:hypernym | |
rdf:type |
|
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:depiction | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |